Overview
Anti-p200 pemphigoid is an autoimmune subepidermal blistering disorder characterized by autoantibodies targeting the 200 kDa protein within the basement membrane zone, leading to mucocutaneous and occasionally cutaneous blistering 1.Diagnosis
Clinical Presentation: Presence of subepidermal blisters, often involving mucous membranes like the oral cavity and eyes 1.
Histopathology: Direct immunofluorescence showing linear deposition of IgG and/or C3 along the basement membrane zone 1.
Serological Testing: Anti-p200 antibody detection via indirect immunofluorescence or ELISA 1.Management
First-Line Treatments:
- Corticosteroids: High-dose systemic corticosteroids (e.g., prednisone) are typically initiated 1.
Adjunctive Treatments:
- Immunosuppressive Agents: Addition of second-line agents such as azathioprine, mycophenolate mofetil, or rituximab may be required for refractory cases 1.
- Antimalarials: Hydroxychloroquine can be considered as adjunctive therapy 1.Special Populations
Elderly: Careful monitoring of immunosuppressive side effects is crucial due to increased vulnerability 1.
Comorbidities: Management should consider potential interactions with existing conditions, particularly those requiring anticoagulation, given the noted risk of venous thromboembolism (VTE) with certain therapies 1.Key Recommendations
Initiate treatment with high-dose systemic corticosteroids for anti-p200 pemphigoid (Evidence: Moderate 1).
Consider dose adjustment or alternative immunosuppressive agents if there is no response or significant side effects, especially VTE risk (Evidence: Weak 1).
Regular monitoring of disease activity and side effects is essential, particularly in elderly patients and those with comorbidities (Evidence: Expert opinion 1).References
1 Stino AM, Bumma N, Smith R, Davalos L, Allen J, Ye JC et al.. Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose. European journal of neurology 2024. link